India: Of Bad Drugs, Deaths And Promises Of Reforms
This article was originally published in PharmAsia News
The recent deaths of 13 women due to contaminated ciprofloxacin administered at a sterilization camp in India, is being seen as a wake-up call for regulators - to both accept shortcomings and chart out a serious plan for regulatory overhaul.
You may also be interested in...
A sharp increase in data integrity findings has raised questions about the quality of pharmaceutical manufacturing in India. What’s happening and why, who’s responsible, and how can drug makers and the regulatory agencies that watch over them put a stop to it?
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.